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E-mail address: r.kitney@imperial.ac.uk (R. KitneyJust over two years ago there was an article in Nature entitled ‘‘Five Hard Truths for Synthetic Biol-
ogy’’. Since then, the ﬁeld has moved on considerably. A number of economic commentators have
shown that synthetic biology very signiﬁcant industrial potential. This paper addresses key issues
in relation to the state of play regarding synthetic biology. It ﬁrst considers the current background
to synthetic biology, whether it is a legitimate ﬁeld and how it relates to foundational biological sci-
ences. The fact that synthetic biology is a translational ﬁeld is discussed and placed in the context of
the industrial translation process. An important aspect of synthetic biology is platform technology,
this topic is also discussed in some detail. Finally, examples of application areas are described.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.It is now just over two years since the article 5 Hard Truths for
Synthetic biology was published [1]. The article looked at some of
the issues relating to synthetic biology at that time. As we will
show, many things have changed in the interim period. Two years
ago there was still considerable doubt about whether or not syn-
thetic biology was likely to have signiﬁcant industrial impact. It
is now pretty clear that the case has been made and that synthetic
biology will have very signiﬁcant impact in a range of ﬁelds – lead-
ing to the development of new, major industries. The evidence for
this statement can be found in a number of sources. For example
the bcc report [2] which predicts that:
 The global value of the synthetic biology market reached $1.1
billion in 2010. It is expected to reach $1.6 billion in 2011 and
it will further grow to $10.8 billion by 2016, increasing at a
compound annual growth rate (CAGR) of 45.8.%.
 The global value of the enabled products segment reached
$944.7 million in 2010. It is expected to reach $1.4 billion in
2011 and will further grow to nearly $9.5 billion by 2016 at a
CAGR of 46.5%.
 The global value of the core products segment reached $109.4
million in 2010. It is expected to reach $126.8 million in 2011
and to grow to $698.8 million by 2016 at a CAGR of 40.7%.cal Societies. Published by Elsevier
).There is, in some quarters, still doubt about the deﬁnition of
synthetic biology. This is not a view held by the international syn-
thetic biology community. (The community can be deﬁned as peo-
ple who attend the major international ‘‘SB X.0’’ [3] conferences
and regularly organise teams for the International Genetically
Engineered Machine Competition (iGEM) [4] – a prestigious stu-
dent competition involving many of the world’s leading universi-
ties.) The accepted deﬁnition is ‘‘synthetic biology aims to design
and engineer biologically based parts, novel devices and systems
– as well as redesigning existing, natural biological systems’’. Syn-
thetic Biology is the application of systematic design – using engi-
neering principles. In addition, whilst much has changed in
synthetic biology over the last two or three years, much of the con-
tent of reports published at that time are still valid, e.g. the Tessy
Report [5] and that of the UK’s Royal Academy of Engineering [6].
1. The arguments against the synthetic biology approach
In simple terms synthetic biology aims to make the engineering
of biological systems easier and more predictable. It also aims to
allow accumulated knowledge on biological systems to be stand-
ardised to enable its utility in the synthetic biology design process.
It is often argued that biological systems cannot be considered as
engineers consider computer mother boards or other electronic de-
vices, and, consequently, the concepts applied to these engineering
disciplines are therefore not applicable in biology. This may be true
at a simple practical level, but conceptually and strategically thereB.V. Open access under CC BY-NC-ND license.
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on the engineering tenets of modularity, standardisation and char-
acterisation [7,8]. The issue with context dependence in biological
systems and the interaction between newly designed genetic cir-
cuits and the host organisms are, legitimate concerns. However,
an important objective of synthetic biology is to constrain biolog-
ical systems by controlling complexity through either the design
of orthogonal genetic circuits that do not interact with the host
system or by using biological processes like directed evolution to
optimise the function of new designed circuits. As we begin to fully
understand the function of single cells at a systems level through
experimental and mathematical modelling, (which is the aim of
systems biology), then our ability to predictably intervene in such
systems will be signiﬁcantly increased. It is important to note that
similar situations exist in other ﬁelds of engineering. One example
is semiconductors (e.g. transistors). Semiconductor physicists and
engineers have worked for many years to constrain semiconduc-
tors to operate according to human designs.
Another major critique to the engineering of biology using syn-
thetic biology approaches is in the nature of living cells. Cells are
constrained volumes of highly concentrated chemical entities.
Both macromolecules and small molecules freely diffuse and/or
are actively distributed within a complex three-dimensional ma-
trix that constitutes the cell. The self-assembly of cellular compo-
nents and stochastic behaviour of living systems provide
signiﬁcant challenges for synthetic biologists. However, living
cells utilise many regulatory elements in their decision-making
processes – using, for example, genetic switches and logic like
inverters, toggle switches, pulse generators and biphasic switches
[9]. They also use sensors like small molecule inducers to activate
transcription of speciﬁc genes or environmental sensors like light
also to active gene networks or cell-cell communications systems
that signal between cells again resulting in a transcriptional re-
sponse. Cells are thus exquisitely evolved to sense and adapt to
their living environments and have genetic circuits that encode
these functions, which synthetic biologists are now adapting for
different applications. One aim of synthetic biology is deﬁne these
genetic modules as functional devices, which can be used in a de-
sign process to create more complex responses or functions. This
has been deﬁned as harnessing ‘natures toolbox’ [10], which with
the expanding metagenome is an exciting prospect for synthetic
biologists. An estimate from existing genome information sug-
gests 5 to 6 million open reading frames (including redundancy)
not including genetic regulator elements, and it is likely that this
number will increase. It is also interesting to consider naturally
occurring DNA encoded functional modules like bacterial operons-
where biological context and complexity have been already en-
coded within the DNA sequence through evolution. The challenge
here is to correctly interface such modules, which again requires a
systematic and cyclical approach.
Another argument against the design of biological systems is
robustness. As cells are highly adapted and exist to replicate,
evolve and/or perform speciﬁc functions, for example in multi-
cellular organisms, they have mechanisms which protect them
from the addition of genetic material that would perturb their
viability. For example, bacteria utilise the host restriction modiﬁ-
cation system where foreign DNA (e.g. form bacteriophage or
viruses) is rapidly degraded by bacterial encoded enzymes. More-
over, molecular biologists have long discovered the random accu-
mulation of mutations in certain cloned plasmids, the products of
which are toxic to the cell during the cloning process and thus are
mutated by the host cell. For synthetic biologists these pose sig-
niﬁcant challenges in that the robustness and functionality of de-
signed synthetic biological circuits could be compromised over
time by the natural host system. Thus one aim of synthetic biol-
ogy is to deﬁne host cells that are tolerant to synthetic biologydesigns either by minimising their natural systems or by deﬁning
areas of the host genome or even insulated cellular compartments
which would incorporate new genetic material with minimal host
effects. These areas could be thought of as ‘islands of robustness’
and although the designed functions of the new synthetic biology
circuits will have a causative effect on the hosts tolerance, the use
of natural biological mechanisms to direct rapid evolution and/or
selection will enable the establishment of more robust systems.
This also extends to the metabolism of the host system, as any
complex synthetic biology circuit e.g. multi-step biosynthetic
pathway will create a burden on the hosts metabolic processes.
This metabolic loading will also induce stress responses that will
again impinge upon the robustness of the newly designed cir-
cuits. Here synthetic biology solutions will include the rewiring
of the hosts transcriptional networks to select optimised hosts
for the particular biosynthetic pathways combined with dynamic
metabolic ﬂux modelling to optimise the regulatory elements of
the newly design pathway. As synthetic biology involves a sys-
tematic engineering approach, what is learned from these proce-
dures will be fully characterised and therefore available to other
researchers. As we learn more about rewiring host cells for syn-
thetic biology design, including dynamic regulatory models of
such processes, we will ultimately be able to carry out in silico
design with a more predictable outcome when implemented
in vivo.
So what is the situation regarding synthetic biology today? The
ﬁrst point to make is that many groups around the world are now
taking a professional engineering approach to synthetic biology.
This is important because one key endpoint of synthetic biology
is industrialisation. (This is not the only endpoint; synthetic biol-
ogy will also have a signiﬁcant impact on the fundamental under-
standing of biological systems, particularly in relation to systems
biology.)2. Synthetic biology industry and foundational science
Even though there is a clear deﬁnition of synthetic biology
which most people in the ﬁeld accept, there is still quite a high de-
gree of misunderstanding about the true nature of the ﬁeld. A clear
distinction must be made between various ﬁelds in life science
(which, in the context of synthetic biology, can be considered to
be foundational science) and synthetic biology itself. A helpful
example is the distinction between physics and engineering –
where physics, in this context, is foundational science for engineer-
ing. Referring to Fig. 1, the right side of the diagram shows the
main ﬁelds of pure and applied science which contribute (in a
foundational sense) to synthetic biology. The left side of the dia-
gram illustrates what comprises synthetic biology and how it re-
lates to industrialisation. Referring to this side of the ﬁgure, three
inputs to synthetic biology are deﬁned: the academic base, Bio-
knowledge and foundational science. The academic base refers to
two things, (a) the basic infrastructure of research-led universities,
and (b) teaching and educational programmes relating to synthetic
biology. There are now a number of leading universities that are
teaching specialist courses in synthetic biology. If the assumption
that synthetic biology will be the source of a range of new indus-
tries and new approaches for existing industry is correct, then a
specially trained workforce will be required to meet these needs.
This problem has already been identiﬁed, which is why there are
now a number of university courses in the area of synthetic
biology.
The section of the diagram that refers to Bio-knowledge relates
to three areas: techniques and methodologies which can be ap-
plied to synthetic biology, background knowledge and naturally
occurring systems.
Fig. 1. Synthetic biology.
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Many of the methods and techniques which are used in syn-
thetic biology are derived from other ﬁelds – this applies to both
the life sciences and physical sciences. For example, synthetic biol-
ogy would not have been possible without fast gene sequencing
and reliable DNA synthesis. Other examples are computer model-
ling and the application of computer aided design (CAD) tech-
niques. (In many cases the methods derived from other ﬁelds are
customised for synthetic biology.) There is, therefore, a technolog-
ical base which has been constructed relatively rapidly by drawing
on experience from other ﬁelds.
2.2. Background knowledge
This is a very interesting aspect of synthetic biology. There are
at least two major areas under this heading. The ﬁrst area is the
application of knowledge from foundational science which is di-
rectly applicable to synthetic biology. An example of this is syn-
thetic DNA introduced into a given host cell e.g. E. Coli. The hosts
currently used in synthetic biology have been chosen because a
great deal of knowledge has been accumulated about these types
of cells which is directly applicable to synthetic biology. The sec-
ond area relates to the concept of parts (or components), devices
and systems. One example of this approach is where a thoroughly
researched aspect of a biological system, which has been studied
purely to understand the biology, is now seen as being part of a
synthetic biology device (often with some modiﬁcation). (The di-
rect analogy here is the difference between pure and applied
mathematics.)
2.3. Naturally occurring systems
This approach is based on the concept that there are naturally
occurring biological entities which have interesting properties
that can be applied to synthetic biology design. One example re-
lates to reporters (or indicators). Green ﬂuorescent protein (GFP)
often forms part of a synthetic biology device to act as a visible
indicator of when a particular event has occurred. GFP was origi-
nally found in naturally ﬂuorescing jellyﬁsh. Their biology was
studied and the protein which caused the ﬂuorescence identiﬁed
and isolated.3. Synthetic biology and platform technology
Referring again to Fig. 1, the three components (the academic
base, Bio-knowledge and foundational science) are all inputs to
the ﬁeld of synthetic biology. The details of platform technology
are covered in the next section, but the term refers to a suite of
tools and methods which can be applied across a range of ﬁelds.
Hence, the platform technology can be applied to a spectrum of
application areas. This is primarily a translational process which
relates to industrial applications. For this process to be effective,
there will be a need to develop new methods of industrial engi-
neering and to modify existing methods. One important example
of this is the development of programmable bio-factories – where
the cell is considered as a manufacturing unit. For this to be
achieved, the host cells used for applications will need to be opti-
mised for particular applications. This may involve developing new
strains of existing cells for industrial purposes (e.g. yeast or E. Coli)
or, in the future, to develop so called minimal cells. Conceptually,
in simple terms, a programmable bio-factory can be thought of
as being roughly equivalent to a computer controlled machine.
The DNA, modiﬁed by the synthetic biology design process, is the
‘‘software’’ that drives the host (i.e. the bio-factory) to produce a
human-deﬁned product. Here, the DNA comprises a number of
components (BioParts) which are interfaced (the DNA of synthetic
biology device). When this DNA is introduced into the host it pro-
duces the ‘‘device’’. In the industrial context, this process will result
in a product [11,12].
Synthetic biology can be thought of as comprising two compo-
nents: (a) the development of platform technology, and (b) appli-
cation projects across a range of ﬁelds – both with potential
impact on systems biology. These will now be considered in turn.
3.1. Platform technology
The term platform technology refers to a suite of tools and
methods which can be applied across a range of ﬁelds. To under-
stand why this is important it is necessary to consider one of the
tenants of synthetic biology, modularity. Here, in common with
other ﬁelds of engineering, the strategy is that standard systems
can be produced from standard devices, which, in turn, are pro-
duced from standards parts (or components). In synthetic biology
an important element of this process is the development of fully
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ing, at present, a part comprises a sequence of DNA, which has cer-
tain characteristics. When such a sequence is placed in a host the
cell responds by producing the pre-deﬁned function (e.g. the pro-
duction of a protein to sense a chemical). This process effectively
is the translation of the encoded information within the designed
DNA sequence. As stated above, the robustness and predictability
of the synthetic biology design poses signiﬁcant challenges. Part
of the systematic design approach is to deﬁne the behaviour of
synthetic biology parts within a particular host such that it is
repeatable. This is the process of Characterisation [13]. Hence,
associated with the Part’s performance are two sets of information
– the characterisation data (which deﬁnes the Part’s behaviour
within the host cell) and the data about the experimental and other
conditions (the metadata). Both sets of information relate to a par-
ticular Part (BioPart) and are stored in a Registry. Currently, a Reg-
istry may contain physical sections of DNA; however, in the future
(and in some instances this is already the case) the DNA Part se-
quence will simply be stored electronically. Hence, the Registry
comprises a Database.
Currently, there are problems with existing Registries of Parts.
For example, in the Registry used for iGEM many of the parts are
not fully characterised. Because of these problems, a number of re-
search groups working on characterisation are now working on
professional registries of parts – which are fully characterised in
the context of the hosts in which they are to be used. The objective
is to achieve a situation where a single part [i.e. speciﬁc type] can
be produced and stored in multiple locations. (This concept has di-
rect equivalence to a particular transistor type being produced by
multiple manufacturers.)
The deﬁnition and production of standard parts, devices and
systems relies on the tools and procedures which comprise the
Platform Technology. In terms of parts and devices, this comprises
three principal sections: host cells, part characterisation and DNA
assembly.
3.1.1. Host cells
As previously stated, the operation of a particular biological part
must be seen in the context of a given host. Hence, in synthetic
biology the process of device or system design is done in the con-
text of a particular host cell (also know as chassis in synthetic biol-
ogy). This means having, as far as possible, detailed knowledge of
the host cells. For this reason, currently there are a number of cell
types that are widely used in synthetic biology – e.g. Escherichia
coli, Saccharomyces cerevisiae and Bacillus subtilis. Detailed informa-
tion and data are stored in the Registry and used in relation to a
particular part. Speciﬁcally, growth characteristics, single cell
behaviour versus population cell behaviour, metabolic loading
and essential gene analyses will be key aspects of host cell charac-
terisation in synthetic biology.
3.1.2. Part characterisation
In order to follow the principles of systematic design and mod-
ularisation, it is essential that the properties of parts and their
functional behaviour are extremely well characterised [14]. In
accurate part characterisation the objective is to ensure that the
process becomes standard – so that the same characterisation data
(the data) for a given part can be obtained at multiple, disparate
locations when the experimental conditions (deﬁned by the meta-
data) are reproduced. Accurate characterisation is designed to en-
sure that parts are compatible (if they are supposed to be
compatible), once the interfacing and context dependency prob-
lems between parts are resolved. The context dependency of bio-
logical systems is a major issue in synthetic biology design and
requires part characterisation to be carried out in many different
contexts. Again, with a systematic and standardised approach,information on part-host compatibility will be learned such that
a standard set of parts with deﬁned functional behaviour within
a given host can be established. It is important to note that signif-
icant control behaviour within synthetic biology circuit designs
can be encoded using a small set of biological parts (e.g. promoters,
ribosome binding sequences etc.)
3.1.3. DNA assembly
In synthetic biology design DNA assembly is a key technology
since complex DNA-encoded designs will require the assembly of
multiple DNA sequences. Moreover, optimisation of functional out-
comes will require an ability to randomly reassemble DNA se-
quences to screen for optimal performance (e.g. the yield of a
biosynthetic product). A number of ways have now been developed
to achieve effective DNA assembly [15]. However, it should be
pointed out that in many cases in synthetic biology commercial
gene synthesis companies are used for this purpose – examples
are Blue Heron, DNA 2.0 and GeneArt (now owned by Life Technol-
ogies). DNA assembly methods can be broken down into two main
of categories: Part assembly (sequential and ordered) and Gene to
Pathway (parallel-ordered and combinatorial, i.e. parallel assem-
bly). In all cases the aim is to achieve assembly through robust,
automated assembly methods. Details of speciﬁc assembly meth-
ods are beyond the scope of this article; however, two of the most
commonly used methods are BioBricks (or standard assembly) and
Gibson [16].
4. Synthetic biology is not Plug and Play
The design and construction of a biological device in synthetic
biology comprises in conceptual terms, building a device from an
assembly of standard parts. Such a statement often leads to misun-
derstandings in which the concept of building standard devices
from standard parts is thought of as one of simply plugging stan-
dard parts together (i.e. so-called Plug and Play). This is a gross
oversimpliﬁcation of the process; it is not what happens in syn-
thetic biology and, indeed, not what happens in many areas of
engineering. Whilst it is true that many engineering devices and
systems are built from standard parts and devices, the process of
connection usually requires careful consideration. Interfacing is
the process of ensuring that if, for example, two standard parts
or devices in isolation behave in a well deﬁned manner, that this
will still be true when they are combined. Frequently, in engineer-
ing, the resolution of interfacing problems requires considerable
time and effort – the same is true in synthetic biology. Neverthe-
less, the power of the approach rests in standardisation and the
ability to routinely replicate a device or system using machinery
(e.g. robots), this is the key to many industrial processes.
The systematic design approach for the construction a biologi-
cal device or system will often require the application of the design
cycle. This comprises a circle of activity, which consists of speciﬁ-
cation, design, modelling, construction and testing, and validation.
Normally, there are several iterations of the design cycle before the
biological device or system performs according to the speciﬁcation.
In synthetic biology there is an additional, important factor which
is part of the process, namely, human practise (i.e. ethical, environ-
mental and societal issues) which form part of responsible innova-
tion and design.5. Integration of the platform technology
The platform technology, which has been described so far – part
characterisation, host cells, and DNA assembly are shown in Fig. 2.
However, the missing piece, which completes the platform tech-
nology, is a web-based information system. SynBIS (synthetic
Fig. 2. Platform technology.
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This has the ability to not only incorporate the characterisation,
host cells and DNA assembly information, but, also, models and
BioCAD tools. SynBIS (when fully completed) has a four layer archi-
tecture comprising a web-interface layer, a communication layer, a
specialist software layer and an SQL database layer. SynBIS will al-
low open-source access by the synthetic biology community to a
wide range of part data and models.
6. The emergence of BioCAD
The aim is that in the future synthetic biology devices and
systems will be designed by designers working with high level
computer code. (As synthetic biology circuits are encoded by
DNA sequences, there are opportunities to make this process
computational.) The term BioCAD or ‘Biological Computer Aided
Design’ has emerged, which encapsulates these efforts. There is a
pretty close analogy between this process and computer program-
ming. In software-based design the designer usually works in a
high level computer language, such as C++. The code at this level
is then automatically translated into an interim level code, called
assembler, and ﬁnally into machine code. A similar schema is being
proposed for synthetic biology in relation to systematic design.
Referring to Fig. 3, blockdiagram design is the equivalent to writing
in high level computer code. There are already a number of
academic and commercial packages which to apply to various
blocks of the diagram (e.g. TinkerCell [18], Gene Designer [19],
Clotho [20] and GenoCAD [21]). In the near future these and other
software packages for synthetic biology design will be integrated
into information environments such as SynBIS.
7. The need for standards in synthetic biology
As mentioned earlier, systematic design in synthetic biology
uses the engineering principles of modularity, characterisation
and standardisation. If synthetic biology devices and systems are
to be accurately reproduced, they must be standardised. It is some-
what surprising that in molecular biology and biological sciences,
in general, there are few standards. This also includes biotechnol-
ogy, and although there are standard protocols (for examplecloning, protein expression, DNA sequencing), there are no stan-
dards in terms of engineered biological function which can be doc-
umented and exchanged between researchers. In synthetic biology
the development of standards is now underway. Currently there
are three under development – SBOL, DICOM-SB and JBEI.
7.1. SBOL
SBOL (synthetic biology open language, [22]) is, essentially, a
standard for the exchange of information, describing DNA compo-
nents used in synthetic biology. In this context, the SBOL standard
deﬁnes: (a) the vocabulary, a set of preferred terms and (b) the core
data model, a common computational representation. The core of
the standard currently comprises the following components, which
are interconnected. The sample, the physical DNA, the Part, the se-
quence annotation, sequence feature, cell, vector and assembly
format.
7.2. DICOM-SB
Research is being undertaken to develop a synthetic biology
extension of the DICOM standard [23]. DICOM is a highly success-
ful standard in biomedicine, which incorporates many features
that are compatible with the requirements of synthetic biology
(e.g. accurate image exchange). Another feature of DICOM is the
ability to store and exchange data and metadata. In addition,
web-based viewers can be incorporated. There are a number of
areas of compatibility between DICOM-SB and SBOL.
7.3. JBEI
This work is part of that being undertaking at the Joint BioEner-
gy Institute [24] and involves their synthetic biology group. JBEI
are developing a parts registry, together with BioCAD tools (this
part of the work also involves incorporating tools from other
sources). The assembly of parts from the registry using automation
tools and high-throughput liquid handling robots is also a feature
of the work.
The common feature of all of the work described here (under
the heading of platform technology) is that it is being carried out
Block Diagram Design
BioPart Block Diagram
Assembly Strategy Software
DNA Assembly
Viability Testing (Wet Lab)
Fig. 3. BioCAD schema.
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thetic biology parts, devices and systems are modular, fully charac-
terised and standardised.
8. Application areas
As described in previous sections of this paper, the strategy in
synthetic biology is to develop platform technology which can be
applied across a wide range of areas. The areas of application need
to be seen in the context of different timescales (short, 3–5 years,
medium, 5–10 years. and long, longer than 10 years). What is
important here is to differentiate between the development of
the applications projects and the ability to establish new product
pipelines within existing industries – as well as the development
of new industries. In a number of cases the objective would be to
break into the supply chain at an early stage. An example of this
is biofuels. Here, it is already the case that the biofuels which are
being produced today can be entered into the supply chain with
relatively minor changes. In terms of longer term developments,
it is likely that synthetic biology can help solve the reliance on pet-
rochemicals. Whilst new, signiﬁcant reserves of oil are being found
on a regular basis, the problem is that the demand is rapidly
increasing – for example the rapid development of demand in Chi-
na and India. What is therefore required is the development of bio-
logically based equivalents, e.g. bio plastics. Synthetic biology has
an important role to play in terms of moving away from oil based
feedstocks to biomass feedstocks. A great hope is that synthetic
biology will lead to much more environmentally friendly products
(where this is built into the design). More directly, there is the
development of new sources of energy from different feedstocks,
including waste.
The topic of applications will now be addressed more
speciﬁcally.
8.1. The application of engineering principles
In this paper we have described how synthetic biology is based
on engineering principles. Whilst the primary aim of the ﬁeld is
industrialisation – i.e. applications leading to products – the tech-
niques and methodology which are being developed will have
signiﬁcant impact on the understanding of biological systems,
particularly in the area of systems biology. Indeed the importance
of engineering science to systems biology was clear recognised in
the Inquiry into systems biology by the Academy of Medical
Sciences and the Royal Academy of Engineering [UK] [25]. In thisregard, the commonality of the two ﬁelds, in terms of basic meth-
ods, has been recognised in a number of books [26–28] –and [29] is
an example of a paper which speciﬁcally addresses the issue of the
application of engineering principles to synthetic biology.
8.2. Examples of applications
In terms of speciﬁc examples, biosensors are seen as an area
where there are likely to be early returns from synthetic biology.
These, of course, are biologically based sensors. Healthcare applica-
tions are an area of development. There are currently several
examples of sensors which have been developed to detect patho-
genic bioﬁlms – two examples being the detection of urinary tract
infection [30,31] and, alternatively, the detection of arsenic in
drinking water. Synthetic biology based designs are also now being
developed for the detection of parasites in water (e.g. a biosensor
to detect Schistosoma). What is already clear is that because of
the systematic modular design approach, a basic design can be
modiﬁed for a range of applications. Biosensors can also be used
as a tool for bioprocess design and optimisation. In any bio manu-
facturing process, a series of conditions can be varied in order to
increase or decrease the yield of the desired product. These include
temperature, pH, dissolved oxygen tension, and the availability of
key nutrients (medium formulation). In many industries, bioproc-
ess development is centred on a combinatorial exploration of these
variables in order to determine which combination leads to the
greatest yield of product. Biosensors can be used to aid process
development and also to provide a greater understanding as to
how process variables affect cellular metabolism in order to move
towards rational process design in the future.
In the simplest case, a biosensor developed to detect the con-
centration of the desired product can be used as an in situ high
throughput screen to maximise production. In one such example,
Santos and Stephanopoulos identiﬁed conditions for the overpro-
duction of L-tyrosine in E. coli using a biosensor circuit that con-
verted the tyrosine into a coloured product called melanin.
Conditions under which melanin accumulated in larger quantities
can then be replicated in the absence of the circuit to accumulate
tyrosine. In this way, both process conditions and genetic variants
can be screened to ﬁnd combinations which lead to overproduction
of tyrosine [32].
Another strategy is to monitor metabolites which are correlated
with productivity as an indirect measure of the best process condi-
tions. This strategy has the advantage of beingmore generalisable as
certain metabolites will be of interest in most systems. Metabolites
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many industrial production systems and their utilisation is already
often monitored online using analytical chemistry techniques – e.g.
[33]. Synthetic biology also allows the development of genetically
encoded solutions for monitoring these key variables and also al-
lows measurements of the intracellular concentrations, which for
some applications is more informative. Recently, in vivo biosensors
based on Förster Resonance Energy Transfer were used to monitor
the concentrations of glucose and glutamine during the fed-batch
cultivation of the industrially relevant protein production host Chi-
nese Hamster Ovary cells. In this study, the authors were able to
show a direct relationship between the ﬂuorescence emission spec-
tra of the cells and the metabolite concentration in a 96-well plate
assay, suggesting the biosensors are appropriate for high through-
put medium formulation studies in well plates [34].
Work is on-going on the development of biologically-based lo-
gic gates (e.g. AND and NAND gates) [35]. (These are the biological
equivalents of their electronic counterparts, which form the basis
of all digital devices – including computers.) Once multiple gate
designs have been perfected they will have wide application in log-
ical devices, e.g. in biosensors (for detection and the release of
drugs, based on inbuilt logic). Ultimately, it should be possible to
implant intracellular, human designed control devices that will
override or replace the natural control and signalling mechanisms.
An example of work in this area relates to in silico feedback in the
control of a gene expression circuit [36].
As with electronic digital devices, the control of Bio-logical de-
vices requires a clock. For this reason the area of controlled biolog-
ical oscillators has been a topic of considerable interest in synthetic
biology for a number of years. An early, well known, example is the
Repressilator [37], which comprises three genes in a feedback loop
– this is, effectively, a form of ring oscillator which uses green ﬂo-
rescent protein (GFP) as its reporter. However, for oscillators to be
really useful, in the context of human-designed biological devices,
they must be controllable and stable in terms of frequency and
amplitude, and have a high signal to noise ratio. Since the Repress-
ilator there have been various attempts to achieve this objective;
for example, by the use of Lotka-Volterra dynamics [38] and a
tuneable synthetic gene oscillator [39] – and, more recently, be
using a synchronised quorum clock approach [40]. A recent exam-
ple of the use of biological oscillators in another area relates to
their application to liquid crystal displays [41]. Again, in the area
of biologically-based digital devices, the issue of rewritable digital
storage in live cells has recently been addressed [42].
High value chemicals (e.g. surfactants and cosmetics) are an-
other important application area, e.g. the metabolic reprogram-
ming of the periwinkle plant [43]. In the pharmaceutical industry
the development of new drugs, based on a much wider range of
natural products, is being investigated – as well as the develop-
ment of new methods for vaccine development and production
[44]. The development of novel materials (e.g. synthetic versions
of naturally occurring materials) is another application area for
synthetic biology. Synthetic spider silk is one example [45].
9. Concluding remarks
 Synthetic biology is a new ﬁeld which is based on the engineer-
ing principles of standardisation, modularisation and character-
isation, coupled to systematic design (it is not a direct extension
of genetic engineering).
 An important driver of synthetic biology, and indeed probably
the key to its genesis, has been the development of increasingly
low cost and reliable gene sequencing and synthesis methods
which are becoming widely commercially available. Industrialisation is an important endpoint of synthetic biology
(i.e. it is primarily a ﬁeld of engineering).
 Whatever the relative economic growth ﬁgures for synthetic
biology, from a variety of sources might be, its economic impact
is generally predicted to be highly signiﬁcant.
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